Form 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

February 14, 2006

Date of Report (Date of earliest event reported)

 

AMGEN INC.

(Exact Name of Registrant as Specified in Charter)

 

Delaware   000-12477   95-3540776
(State or Other Jurisdiction
of Incorporation)		   (Commission
File Number)		   (I.R.S. Employer of
Identification Number)

 

Amgen Inc.    
One Amgen Center Drive    
Thousand Oaks, CA   91320-1799
(Address of Principal Executive Offices)   (Zip Code)

 

805-447-1000

(Registrant’s Telephone Number, Including Area Code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 8.01. Other Events.

 

On February 14, 2006, Amgen Inc. announced the pricing of its previously announced private offering of $2.5 billion principal amount of 0.125% Convertible Senior Notes due 2011 and $2.5 billion principal amount of 0.375% Convertible Senior Notes due 2013. A copy of the press release is attached hereto as Exhibit 99.1, is incorporated herein by reference, and is hereby filed.

 

Item 9.01. Financial Statements and Exhibits.

 

Exhibit No.
   

Document Description

99.1    Press release, dated February 14, 2006.

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

       

AMGEN INC.

Date: February 14, 2006

      

By:

  

/s/ Richard D. Nanula

           

Name:

  

Richard D. Nanula

           

Title:

  

Executive Vice President and Chief Financial Officer

 

EXHIBIT INDEX

 

Exhibit No.
   

Document Description

99.1    Press release, dated February 14, 2006.